-
Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D
•
Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of Dr. Rafael G. Amado as President and Global Head of Cancer Research and Development (R&D), effective December 30, 2022. Dr. Amado will join the company’s management committee as a core member, reporting directly to Dr.…
-
Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors
•
China – based Jiangxi Jemincare Group has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its Category 1 drug JYB1907. The monoclonal antibody (mAb) targets glycoprotein A dominant repeat (GARP) and transforming growth factor – β1 (TGF –…
-
Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases
•
China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study assessing its Category 1 drug candidate 9MW3011 for the treatment of β – thalassemia and polycythemia vera. The drug, which already…
-
Staidson’s Anti-C5a Monoclonal Antibody STSA-1002 Accepted for NMPA Review
•
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced that the clinical trial filing for its injectable STSA-1002, an anti-human complement protein C5a (hC5a) monoclonal antibody (mAb) for use in acute respiratory distress syndrome (ARDS), has been accepted for review by the National Medical Products Administration (NMPA). About ARDS…
-
Guangdong Raynovent Biotech Secures RMB 370 Million in Series C Financing
•
Guangdong Raynovent Biotech Co., Ltd, a controlling subsidiary of China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), has reportedly raised RMB 370 million (USD 53.72 million) in a Series C financing round. The round was co-led by Yide Private Equity Investment Fund Management (Guangzhou) Co., Ltd and Efung Capital, with…
-
Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun as its deputy general manager and chief strategy officer (CSO). Dr. Jiang will be tasked with overseeing clinical studies and driving business expansion. Moving forward, Sun Piaoyang, Zhang Lianshan, and Dr. Jiang Ningjun will form…
-
Junshi Biosciences’ CGRP Monoclonal Antibody JS010 Accepted for NMPA Review
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the clinical trial filing for JS010, its in-house developed CGRP monoclonal antibody drug candidate for treating migraine, has been accepted for review by the National Medical Products Administration (NMPA) in China. About CGRP and JS010CGRP is a neuropeptide composed of…
-
BeiGene’s Tislelizumab Receives NMPA Review for First-Line HCC Indication
•
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that a supplementary Biologic License Application (sBLA) for its programmed death-1 (PD-1) inhibitor tislelizumab has been accepted for review by the National Medical Products Administration (NMPA). The latest prospective indication is for the drug’s use in first-line unresectable or metastatic hepatocellular…
